若生智能
Drug Database
TR

tramadol (Qdolo)

✓ Approved

Athena Bioscience, LLC · 小分子 · 小分子

什么是 tramadol？

tramadol 是一种小分子，由Athena Bioscience, LLC研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Qdolo
公司Athena Bioscience, LLC
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Athena Bioscience, LLC

治疗适应症

tramadol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved

相关研究文献

PubMedCureus2026-07-27

Assessment of Drug Utilization Pattern of Antimicrobials Prescribed in the Orthopedic Department of a Tertiary Care Hospital.

Patil Kartiki P KP, Thorat Vandana M VM, Chawla Leesha L LL

Introduction The purpose of prescription patterns is to collect valid data, which would help in formulating appropriate guidelines to ensure the rational use of medicines. Unfortunately, information about the use of medicines in patients visiting orthopedic clinics in tertiary care hospitals in India, especially in Maharashtra, is scanty. Therefore, the present study was undertaken with the primary objective to evaluate the current drug-prescribing trend of antimicrobials in the management of inpatients of the orthopedic department and secondary objectives to assess group-wise distribution of antimicrobials prescribed to inpatients of the orthopedic department and to assess additional drugs prescribed to these patients. Methods This study was a cross-sectional observational study done on 99 patients who were admitted to the wards of the orthopedics department of the hospital. The drug utilization assessment was done by using the WHO core drug prescribing indicators. The assessment of the drugs prescribed according to the essential drug list was done using the National List of Essential Drugs Medicines (NLEM) 2022 of India. Results The study population was predominantly elderly (47.5% ≥60 years) with male predominance (62.6%), and falls (58.6%) as the leading cause, followed by road traffic accidents (35.3%). Antimicrobial use was dominated by broad-spectrum agents, particularly ceftriaxone (43.4%), ciprofloxacin (47.5%), and metronidazole (54.5%), with moderate use of aminoglycosides (35.4%). Fixed-dose combinations were led by Cefuroxime + Sulbactam (25.2%). Supportive therapy was extensive, including ranitidine (62.6%), tramadol (59.6%), antihypertensives, insulin, and nutraceuticals. Combination therapies such as Bromelain + Trypsin + Rutoside (37.4%) were frequently used. Conclusion This study reflects a pattern of polypharmacy characterized by extensive use of broad-spectrum antimicrobials and adjunctive therapies, emphasizing the need for rational prescribing practices and antimicrobial stewardship to optimize clinical outcomes and minimize resistance.

PMID 42504368
阅读全文 →
PubMedMedical sciences (Basel, Switzerland)2026-07-27

Trends in Co-Prescribing Opioids and Gabapentinoids Among Medicare Beneficiaries, 2017 to 2022.

Raji Mukaila M, Sujit Aashnika A, Westra Jordan J, Rajagopal Shilpa S et al.

Co-prescribing opioids and gabapentinoids (GABA, gabapentin and pregabalin) is associated with increased risk of falls, fractures, opioid overdose and deaths. The Centers for Disease Control and Prevention (CDC) in 2016 and the Food and Drug Administration (FDA) in 2019 recommended caution in such co-prescribing. A key step in updating policy and revising prescribing guidelines aimed at reducing opioid and GABA co-use and its associated consequences is a thorough understanding of the prescriber and the patient factors associated with co-use. We thus examined national trends and patterns in opioid and GABA co-prescribing among Medicare beneficiaries from 2017 to 2022. We conducted a retrospective study of Medicare beneficiaries with ≥90 consecutive days of opioid use from 2017 to 2022. The study outcome was GABA use during the 90-day opioid use episode. A multivariable logistic regression model was constructed to examine the patient, prescriber and prescription factors associated with receiving a GABA prescription. Our sample comprised 8035 opioid-only and 2818 opioid and GABA users. Non-cancer (e.g., back and neuropathic) pain was a more common diagnosis in the opioid and GABA cohorts than in the opioid-only cohorts. The opioid-GABA co-prescribing rate did not substantially change (2017: 24.5%, 2019: 28.2% and 2022: 25%). Co-prescribing rates were higher in non-white patients, those on Medicaid and Medicare, and those whose initial Medicare entitlement was not based on age. Tramadol and hydrocodone were the most prescribed opioids. Approximately 33% of opioid and GABA users started with an initial daily GABA dose of ≥1200 mg. In the 12-month lookback period, patients on opioids and GABA had nearly 17 clinic visits to approximately 8 different providers. Factors associated with co-prescribing were seeing pain physicians (odds ratio = 1.29, 95% confidence interval-[CI] = 1.11-1.50), having more healthcare encounters (6-11 visits, odds ratio-[OR] = 1.19, 95% CI = 1.02-1.39; 12-19, OR = 1.20, 95% CI = 1.00-1.43; 20+, OR = 1.27, 95% CI = 1.03-1.57) and seeing >10 providers (OR = 1.40, 95% CI = 1.12-1.73). One in four Medicare beneficiaries with long-term opioid use received opioid and GABA prescriptions. Our findings of association in co-prescribing with multiple visits to different clinics/prescribers can inform the development of public health policy and practice guidelines (e.g., prescription-drug monitoring program checks within electronic medical records, EMR alerts with opioid and GABA co-prescribing) to potentially reduce opioid and GABA prescriptions and associated adverse outcomes.

PMID 42506314
阅读全文 →
PubMedJournal of environmental management2026-07-26

Hybrid green wall - ozonation system for greywater and rainwater reclamation in a residential building: technical performance and social insights.

Mendoza Esther E, Herrán-Morueco Èric È, Riva Massimiliano M, Beral Henry H et al.

Growing water scarcity calls for sustainable and decentralized strategies to reduce demand for freshwater resources. Greywater reuse is a promising option, though concerns about pathogens and organic micropollutants (OMPs) necessitate effective treatment. This study evaluates a full-scale system integrating a green wall with ozonation, installed on a residential building in Sant Quirze del Vallès (Barcelona, Spain), for greywater and rainwater treatment and reuse in toilet flushing. Over one year, the green wall achieved high removal of COD (84%), BOD5 (96%), TOC (87%), TSS (94%), and ammonium (>99%), with ozonation providing additional polishing and ensuring microbial safety (E. coli below the detection limit). Several OMPs, including caffeine, benzotriazole, and tramadol, were effectively removed by the green wall, while ozonation addressed more persistent compounds such as DEET or valsartan. The treated effluent consistently met Spanish quality standards for non-potable reuse. Social acceptance was assessed through resident surveys and stakeholder interviews. While participants acknowledged the environmental value of water reuse, acceptance was influenced by practical concerns (odour, noise or water colour) and trust in the managing entity. Findings highlight the need to complement strong technical performance with effective communication and reliable maintenance to foster long-term adoption of such nature-based and hybrid solutions.

PMID 42501640
阅读全文 →
PubMedTurkish journal of medical sciences2026-07-25

Comparison of ultrasound-guided serratus posterior superior intercostal plane block and thoracic paravertebral block for postoperative analgesia after breast surgery: a prospective randomized noninferiority trial.

Kotanoğlu Mustafa Sırrı MS, Zengin Musa M, Küçük Onur O, Sezgi Atakan A et al.

This noninferiority trial aimed to evaluate whether the serratus posterior superior intercostal plane block (SPSIPB) provides noninferior postoperative analgesia compared with the thoracic paravertebral block (TPVB) after unilateral mastectomy. This prospective, randomized, assessor-blinded, parallel-group noninferiority trial enrolled 60 female patients scheduled for elective unilateral mastectomy. Patients received either ultrasound-guided SPSIPB (n = 30) or TPVB (n = 30) with 30 mL of 0.25% bupivacaine before induction. The primary outcome was visual analogue scale (VAS) pain scores (0-100 mm) at rest and during coughing over 24 h. Noninferiority was assessed using the Hodges-Lehmann median difference with 95% confidence intervals (CIs) and a prespecified margin of 13 mm, corresponding to the validated minimal clinically important difference (MCID). Secondary outcomes included opioid consumption, area under the curve (AUC) for cumulative pain burden, and patient satisfaction. All 60 patients completed the study. At the first postoperative hour, TPVB provided lower VAS scores at rest (median 10.0 vs. 23.0 mm, 95% CI of difference: 0 to 19). For resting VAS, noninferiority was demonstrated at 0 h, 4 h, and 24 h (upper bounds: 11.5 mm, 12.5 mm, and 5.0 mm). The 24-h AUC for resting VAS was comparable between groups (426 mm/h vs. 426.5 mm/h, p = 0.652). SPSIPB produced significantly lower tramadol consumption in the 12-to-24-h interval (median 0 vs. 50 mg, p < 0.001). However, total opioid consumption over the 24 h was comparable (p = 0.070). No block-related complications occurred in either group. Noninferiority of SPSIPB to TPVB was demonstrated for resting pain scores at the majority of postoperative time points after unilateral mastectomy. TPVB provided a transient early-phase analgesic advantage at 1 h and 2 h, while SPSIPB was associated with late-phase opioid sparing. The comparable cumulative pain burden across 24 h suggests that SPSIPB may serve as a periparavertebral alternative to TPVB when sustained analgesia and opioid reduction are clinical priorities.

PMID 42499438
阅读全文 →
PubMedEnvironmental monitoring and assessment2026-07-24

Wastewater-based assessment of episodic changes in psychoactive compounds and hormones during music festivals.

Tulipánová Alexandra A, Mackuľak Tomáš T, Horáková Ivana I, Imreová Zuzana Z et al.

This study investigated 11 psychoactive contaminants in wastewater influents at a municipal wastewater treatment plant in Slovakia between 2015 and 2018, based on 44 samples collected under regular conditions and an additional five samples collected during two music festivals in 2018. In addition, 17 progestagens were analyzed only in 2018 during festival days and their corresponding background days. Seasonal variation in normalized mass loads was generally minor, whereas interannual differences were more pronounced, particularly for psychoactive pharmaceuticals, which showed an overall decrease in 2018. Short-term but substantial increases in contaminant loads were observed during the festivals. During the multi-genre music festival, the normalized mass load of 3,4-methylenedioxymethamphetamine increased by more than 110-fold on the second festival day compared to the pre-festival average, while benzoylecgonine increased approximately 17-fold and dienogest by 1.3-fold. During the country/folk music festival, tramadol loads increased approximately twofold. Principal component analysis explained 70.75% of the total variance using the first two components and revealed a clear separation between festival and background samples. Overall, the results demonstrate that music festivals represent episodic pollution events capable of markedly altering wastewater influent composition over short time periods.

PMID 42496902
阅读全文 →
PubMedNigerian medical journal : journal of the Nigeria Medical Association2026-07-23

Opioid Addiction Medicine in Nigeria: Bridging Clinical Gaps in a Silent Epidemic-A Narrative Review.

Albert Ovie Martin OM

Opioid use disorder (OUD) is an emerging public-health challenge in Nigeria, driven largely by non-medical use of tramadol and codeine and compounded by limited access to evidence-based care. This narrative review synthesises evidence on the epidemiology, patterns, harms and treatment gaps for OUD in Nigeria and identifies priorities for policy and research. We searched PubMed/MEDLINE, Embase, PsycINFO, the Cochrane Library, African Journals Online, Google Scholar and grey literature from 2005 to 2024 for Nigerian data on non-medical opioid use, clinical harms, opioid agonist therapy (OAT) services, barriers and community supports. Findings were thematically synthesised using Braun and Clarke's framework, with quality appraisal using Joanna Briggs Institute tools and the SANRA scale. Thirty studies were included. The 2019 national drug use survey estimated past-year opioid use at 4.7% (approximately 4.6 million people), with institution-based surveys reporting high lifetime misuse among undergraduates. Reported harms included overdose, seizures, psychiatric comorbidity and injectable pentazocine dependence with severe soft-tissue infections. OAT availability remains highly centralised, with limited community recovery infrastructure. Nigeria's OUD burden is substantial but unevenly characterised, highlighting the need to decentralise OAT, integrate addiction training, strengthen surveillance and expand community supports.

PMID 42488855
阅读全文 →

注册免费账户还可查看另外 7590 篇文献

免费注册查看全部文献 →

了解更多tramadol